CD267 (TACI) Antibody, anti-human, REAfinity™
Synonyms: TNFRSF13B, CVID, CVID2, IGAD2, RYZN, TACI, TNFRSF14B
RECOMBINANT EXTENDED VALIDATION
Clone:
REA1229 | 1A1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD267 (TACI) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
PE-Vio 670
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-124-332, 130-124-337
Description:
Human peripheral blood cells (PBMCs) were stained with CD267 (TACI) antibodies or with the corresponding REA Control (S) antibodies (left image), as well as with CD19 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
Extended validation for CD267 (TACI) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1229
1A1
high
1A1-K21-M22
high
11H3
low

Cells were incubated with an excess of purified unconjugated CD267 (TACI) (REA1229) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD267 (TACI). Human peripheral blood mononuclear cells (PBMCs) were stained with CD267 (TACI) antibodies followed by a suitable counterstain. As a control, CD267 (TACI) antibody staining was omitted and cells were measured in the same channel. Flow cytometry analysis was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. The recommended titers of respective antibodies from different suppliers were used

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD267 (TACI) (REA1229). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD267 (TACI) Antibody, anti-human, REAfinity™
Overview

Clone REA1229 recognizes the human CD267 antigen, a 32 kDa type III transmembrane protein belonging to the TNF receptor superfamily. CD267 as receptor binds to BAFF and APRIL and plays an important role in the stimulation of B- and T-cell function and in the regulation of humoral immunity. CD267 expression is found in CD27+ memory B cells, tonsillar and bone marrow plasma cells, in a subpopulation of activated CD27-, non GC cells and in a small subset of naïve blood and tonsil B cells. CD267 is also expressed on many lymphomas such as multiple myeloma and Hodgkin and non-Hodgkin lymphomas. Mutations in CD267 are often associated with common variable immunodeficiency in humans. Signaling via CD267 leads to activation of the transcription factors NFAT, AP1, and NF-kappa-B.

Additional information: Clone REA1229 displays negligible binding to Fc receptors.

Alternative names

TNFRSF13B, CVID, CVID2, IGAD2, RYZN, TACI, TNFRSF14B

Detailed product information

Technical specifications

Clone
REA1229
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD267 (TACI)
Molecular mass of antigen [kDa]
32
Distribution of antigen
B cells
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD267 (TACI) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD267 (TACI) Antibody, anti-human, REAfinity™
Publications
  1. Mackay, F. et al. (2008) TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 19 (3–4): 263-276
  2. Salzer, U. et al. (2005) Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37 (8): 820-828

You have previously chosen International as your location.
What do you want to do?